Teva Settles With Lupin Over Austedo Patent

Teva Pharmaceuticals and Lupin have settled their patent dispute over Lupin’s generic version of Teva’s Huntington’s disease drug, Austedo (deutetrabenazine).

Under the terms of the settlement, Lupin will be permitted to sell its generic deutetrabenazine beginning in April 2033.

Teva, which is still in litigation with Aurobindo over its generic version of the drug, projects that Austedo will generate approximately $1 billion in sales this year.